Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 233

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities

Open access
Hayn, Manuel, Hirschenberger, Maximilian, Koepke, Lennart, Nchioua, Rayhane, Straub, Jan Hendrik, Klute, Susanne, Hunszinger, Victoria, Zech, Fabian, Prelli Bozzo, Caterina, Aftab, Wasim, Christensen, Maria Hønholt, Conzelmann, Carina, Müller, Janis Alexander, Srinivasachar Badarinarayan, Smitha, Stürzel, Christina Martina, Forne, Ignasi, Stenger, Steffen, Conzelmann, Karl-Klaus, Münch, Jan, Schmidt, Florian Ingo, Sauter, Daniel, Imhof, Axel, Kirchhoff, Frank, Sparrer, Konstantin Maria Johannes · 2021 · Cell Reports

Abstract

The innate immune system constitutes a powerful barrier against viral infections. However, it may fail because successful emerging pathogens, like SARS-CoV-2, evolved strategies to counteract it. Here, we systematically assessed the impact of 29 SARS-CoV-2 proteins on viral sensing, type I, II and III interferon (IFN) signaling, autophagy and inflammasome formation. Mechanistic analyses show that autophagy and type I IFN responses are effectively counteracted at different levels. For example, Nsp14 induces loss of the IFN receptor, whereas ORF3a disturbs autophagy at the Golgi/endosome interface. Comparative analyses revealed that antagonism of type I IFN and autophagy is largely conserved, except that SARS-CoV-1 Nsp15 is more potent in counteracting type I IFN than its SARS-CoV-2 ortholog. Altogether, however, SARS-CoV-2 counteracts type I IFN responses and autophagy much more efficiently than type II and III IFN signaling. Consequently, the virus is relatively resistant against exogenous IFN-α/β and autophagy modulation but remains highly vulnerable towards IFN-γ and -λ treatment. In combination, IFN-γ and -λ act synergistically, and drastically reduce SARS-CoV-2 replication at exceedingly low doses. Our results identify ineffective type I and II antagonism as weakness of SARS-CoV-2 that may allow to devise safe and effective anti-viral therapies based on targeted innate immune activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2021.109126

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 233

Metadata

Authors
Hayn, M., Hirschenberger, M., Koepke, L., Nchioua, R., Straub, J. H., Klute, S., Hunszinger, V., Zech, F., Prelli Bozzo, C., Aftab, W., Christensen, M. H., Conzelmann, C., Müller, J. A., Srinivasachar Badarinarayan, S., Stürzel, C. M., Forne, I., Stenger, S., Conzelmann, K.-K., Münch, J., Schmidt, F. I., Sauter, D., Imhof, A., Kirchhoff, F., & Sparrer, K. M. J.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2021-05
Volume
35
Issue
7
Pages
109126
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3157249971
Cited by
233
References
17
FWCI
15.25
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. https://app.cochat.ai/papers/10.1016/j.celrep.2021.109126
The paper
Hayn, M., Hirschenberger, M., Koepke, L., Nchioua, R., Straub, J. H., Klute, S., Hunszinger, V., Zech, F., Prelli Bozzo, C., Aftab, W., Christensen, M. H., Conzelmann, C., Müller, J. A., Srinivasachar Badarinarayan, S., Stürzel, C. M., Forne, I., Stenger, S., Conzelmann, K.-K., Münch, J., . . . Sparrer, K. M. J. (2021). Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. Cell Reports. https://doi.org/10.1016/j.celrep.2021.109126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.